LCB84
LCB84 is an experimental monoclonal antibody from LigaChem Biosciences in phase 2 trials, aimed at TROP2.
Overview
LCB84 is a monoclonal antibody developed by LigaChem Biosciences. Its target is TROP2. ClinicalTrials.gov describes the intervention as: TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05941507, plans to enrol 300 participants with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"LCB84" OR ABSTRACT:"LCB84") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LCB84, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentLCB02A
Shares LigaChem Biosciences and the tags pipeline, ctgov-ingest.
- TreatmentBIO-106
Shares TROP2 and the tags pipeline, ctgov-ingest.
- TreatmentEB-NK-301
Shares TROP2 and the tags pipeline, ctgov-ingest.
- TreatmentA166
Shares the tags pipeline, ctgov-ingest.
- TreatmentAAA817
Shares the tags pipeline, ctgov-ingest.
- TreatmentABBV-706
Shares the tags pipeline, ctgov-ingest.
- TreatmentAbexinostat
Shares the tags pipeline, ctgov-ingest.
- TreatmentABSK061
Shares the tags pipeline, ctgov-ingest.